Dr Najah Abi-Gerges

Dr Najah Abi-Gerges began their professional career in 2000 as a Postdoctoral Fellow at Paris XI University in France. In 2001, they joined AstraZeneca as an Associate Principal Scientist and Senior Scientist. In 2007, they became an Honorary Senior Lecturer at the University of Liverpool. In 2015, they began their tenure at AnaBios Corporation as the Vice President of Research & Development and Scientific Director. In 2016, they became the Editor of the Journal of Pharmacological and Toxicological Methods. In 2020, they were appointed President of the Society of Toxicology Southern California Chapter. Most recently, in 2022, they took on the role of Associate Editor at Frontiers in Physiology - Cardiac Electrophysiology Section.

Dr Najah Abi-Gerges began their educational journey in 1988 when they earned their Baccalauréat “University Entrance Qualification” from High School Jdeidé in Lebanon. Dr Najah then went on to obtain a Master's degree in Animal Physiology from the Lebanese University in Lebanon from 1989 to 1993. In 1994, they earned a Master's degree in Research in Physiology and Pharmacology from Poitiers University in France. The following year, they earned a DEA Qualification in Structures and Functions of Integrated Biological Systems from Paris XI University in France. Finally, they completed their Doctor of Philosophy (PhD) in Cardiac Physiology from Paris XI University in France from 1996 to 1999.